Shares of Regeneron Pharmaceuticals Inc. (REGN) were down 0.2% in trading on Friday after the company said its monoclonal antibody cocktail has been authorized in Europe, both as a treatment and to prevent COVID-19 in cases when someone has been exposed to the virus. The cocktail is called Regen-Cov in the U.S., where it is authorized, and Ronapreve in Europe, where it can now be used in individuals who are at least 12 years old with confirmed cases of COVID-19 and who are at high risk of severe disease. The treatment is authorized in about 40 countries, including Australia, the U.K., and India. Regeneron's stock is up 29.4% so far this year, while the broader S&P 500 has gained 23.8%.
(END) Dow Jones Newswires
November 12, 2021 10:38 ET (15:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.